rttnews.com
Top Biotech Gainers: SNSE Awaits Data In 2H, STTK To Begin Crohn's Trial In Q3, ALMS On Watch
A new Phase 2 Crohn’s trial is planned for Q3 2026 of an investigational DR3‑blocking antibody (SL‑325), which could become a novel treatment approach if later trials show benefit. The report is an investor roundup, so it signals development progress but not clinical proof of benefit yet.
Patients with Crohn’s disease, clinicians following emerging biologic therapies, and researchers interested in DR3/immune‑pathway targeted drug development.
What To Know
Shattuck Labs (STTK) plans to start a Phase 2 trial of its DR3‑blocking antibody SL‑325 in Crohn’s disease in Q3 2026 after Phase 1 safety and PK data in healthy volunteers. The article is a market/biotech roundup summarizing upcoming clinical milestones for several companies rather than a detailed clinical study report.
What To Know Shattuck’s SL‑325 is a novel monoclonal/bispecific DR3 blocking antibody being developed for Crohn’s disease and other immune-mediated conditions.
The company reported a Phase 1 first‑in‑human study in healthy participants that assessed safety, tolerability, PK, immunogenicity, and PD, and said the candidate was well tolerated across a range of doses. Based on those results, Shattuck expects to begin a Phase 2 trial in Crohn’s disease in the third quarter of 2026.
This article is a finance-focused summary, so it does not provide trial design details, timelines beyond the planned start quarter, or patient eligibility and endpoints. It also mentions other companies and programs (Sensei, Alumis) with unrelated indications and milestones.
If you’re tracking potential new Crohn’s treatments, SL‑325 is one to watch for Phase 2 enrollment updates and later efficacy/safety results. For treatment decisions, rely on your care team and peer‑reviewed clinical data rather than early company announcements.
This is a business/market news roundup — details are limited. The Phase 1 results referenced were in healthy volunteers, not patients, and the article does not report efficacy data. Early trial starts are milestones but do not guarantee later success.
